Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that platelet rich plasma (PRP) is a safe and effective treatment for alopecia areata, with no significant difference in efficacy between activated and non-activated PRP.

This letter raises questions for the authors of a recent study on platelet-rich plasma for androgenetic alopecia, without presenting new clinical results.

This case report highlights a rare instance of permanent hair loss caused by an allergic reaction to a mesotherapy mixture containing triamcinolone acetonide, suggesting that hypersensitivity reactions to such mixtures are possible.

This study reports the first documented case of sweat hypersensitivity and progressive sebaceous adenitis in a horse, highlighting the potential for sweat-induced urticaria when exercising or under sedation.

This study reported remarkable improvement in three patients with treatment-resistant alopecia areata after receiving autologous platelet-rich plasma injections, suggesting the potential for this approach and a need for further randomized, placebo-controlled trials.

This case report suggests that intradermal botulinum toxin type A may alleviate pruritus and reduce papules in Fox-Fordyce disease, improving quality of life without serious adverse effects for at least six months.

This study found that adding platelet-rich plasma to 5% minoxidil treatment improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone.

This article discusses various diagnostic techniques for investigating equine skin diseases and reports no new clinical results.

This case report describes a 24-year-old woman with a rare giant cerebriform pigmented nevus on the scalp, which was identified as a giant congenital intradermal nevus based on clinical and pathological findings.

The document concludes that while some hair and scalp disorders can be treated, hair loss from destroyed follicles is permanent, and damaged hair can only regrow naturally.

This paper highlights the emerging trend of treating androgenic alopecia with botulinum toxin, despite insufficient scientific evidence supporting its effectiveness.

This study found that combining needle-free intradermal minoxidil delivery with standard topical minoxidil therapy improved early hair growth parameters and satisfaction in women with early-stage female pattern hair loss compared to topical therapy alone, with no serious adverse events reported over the 10-week period.

This study reported that patients with mild to detectable androgenetic alopecia showed subjective improvement and a favorable safety profile after receiving a polynucleotide-based intradermal gel, with only one case of mild injection-site erythema noted among 60 participants over three months.

In this study, Sper-12/siRNA nanoparticles effectively suppressed abnormal AR protein levels, promoted hair follicle proliferation, and alleviated hair loss symptoms in androgenetic alopecia model mice, providing a promising delivery platform for siRNA-based therapeutics.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study reviewed evidence for six minimally invasive treatments for androgenetic alopecia, finding consistent support for platelet-rich plasma and topical finasteride, while other options like microneedling and intradermal dutasteride showed promise but need further and standardized research.

This case report details a 28-year-old male with early-stage androgenetic alopecia who experienced significant hair density and thickness improvements following a three-month platelet-rich plasma therapy regimen, supporting its potential efficacy in similar cases.

In this case report, a 28-year-old male with androgenetic alopecia experienced significant improvement in hair density and shaft thickness after a three-month platelet-rich plasma therapy regimen, supporting existing literature on PRP's efficacy for early-to-moderate hair loss.

This study found that intradermal polynucleotide injections were linked to improvements in the appearance around the eyes and increased patient satisfaction, with minimal adverse effects, suggesting potential for further research to validate efficacy and optimize treatment protocols.

This study explored recent advancements in hair restoration, particularly focusing on plant-derived exosomes and biomimetic polypeptides, which enhance hair follicle regeneration and growth, offering a promising alternative to human or animal-derived exosomes subject to FDA restrictions.

This case report suggests that combining platelet-rich plasma therapy with mesotherapy may effectively increase hair density and improve scalp health in complex cases of androgenetic alopecia.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.

This review reports that while botulinum toxin shows potential mechanisms for treating androgenetic alopecia, recent high-quality trials found no significant hair density improvement compared to placebo, indicating it can't yet replace traditional treatments.

In this review, the authors assessed the efficacy of mesotherapy for alopecia treatment, finding that combining mesotherapy with minoxidil, PRP, or growth factors significantly improves hair density and thickness but noted the need for standardized protocols and larger studies to confirm long-term effectiveness.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This study found that platelet-rich plasma significantly improved hair density and thickness compared to monofilament thread implantation in treating androgenetic alopecia.

This study reported that intradermal injections of stem cell exosomes appeared safe and significantly improved hair density and diameter in male androgenetic alopecia patients over 24 weeks, suggesting the therapy may be a promising new treatment option worthy of further investigation.

In this study, researchers developed a new microneedle patch delivery system for minoxidil, which enhanced its controlled release and improved hair growth in mice, potentially offering better treatment outcomes for androgenetic alopecia.

This study found that a novel bioengineered microneedle patch successfully delivered minoxidil to induce hair growth in a mouse model, suggesting a promising approach to improve treatment for androgenetic alopecia.

In this report, four cases of noncicatricial alopecia developed following a single session of dutasteride mesotherapy in patients with androgenetic alopecia, highlighting potential adverse effects and the need for careful monitoring of the drug's composition.